Search | Clinical Trials Finder

Conditions: Aging
Interventions: Motor Practice of a Standing Serial Reaction Time Task; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 95 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
Interventions: Everolimus; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Years to 21 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 18
States / cities: Los Angeles, California • Oakland, California • San Diego, California + 14 more

Conditions: PTSD, Marital Relationship
Interventions: CBCT for PTSD, Prolonged Exposure; Behavioral
Lead sponsor: Toronto Metropolitan University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Fort Hood, Texas • Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Spinal Cord Injuries, Polytrauma, Burn Injury, Pain Management
Interventions: Placebo, Oxycodone, Essential Oil; Drug · Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Arteriovenous Graft
Interventions: SRM003, Participating Site's standard practice; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 40 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK4527363, Placebo matching GSK4527363, Belimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more

Conditions: Gonorrhoea
Interventions: Cefixime; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild Cognitive Impairment
Interventions: Deferiprone, Placebo phase; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pediatric Pain, Chronic Pain, Widespread, Musculoskeletal Pain
Interventions: Graded Exposure Therapy (GET Living), Multidisciplinary Pain Management (MPM); Behavioral
Lead sponsor: Laura E Simons; Other
Eligibility: 8 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Sleep Disturbance, Sleep, Depression, Suicide
Interventions: Sleep Feedback + Psychoeducation, Transdiagnostic Sleep and Circadian Intervention + Bright Light (TSC+), Triple Chronotherapy (TCT+); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 25 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions: Alisertib, Pazopanib; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stroke, Hemiparesis
Interventions: In Motion Rehabilitation Robot; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 124
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more

Conditions: Central Nervous System Neoplasms, Head and Neck Neoplasms
Interventions: EPO906 (epothilone B); Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Duarte, California • Newnan, Georgia

Conditions: Caloric Intake and Energy Metabolism
Interventions: Digital Photography of Foods, doubly labeled water, IDEEA, low-calorie diet, Actical, Sensewear Armband; Behavioral · Other · Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Healthy Volunteers
Interventions: Fedratinib, Digoxin, Rosuvastatin, Metformin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions: Momelotinib, Best Available Therapy (BAT); Drug
Lead sponsor: Sierra Oncology LLC - a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 13
States / cities: Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more

Conditions: Limb Deficiencies, Pediatric ALL
Interventions: iFIT prosthesis; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 3 Years to 18 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Aging, Accidental Falls
Interventions: tES (transcranial electrical stimulation); Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 60 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Cervical Cancer, Cancer, Head and Neck Cancer
Interventions: ADXS11-001, MEDI4736; Drug
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 14 more

Conditions: Transitional Cell Carcinoma, Bladder Neoplasms, Kidney Neoplasms, Ureter Neoplasms, Bladder Cancer, Neoplasm, Bladder
Interventions: vinflunine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 38
States / cities: Beverly Hills, California • La Jolla, California • Los Angeles, California + 35 more

Conditions: Pancreatitis
Interventions: Sodium Phosphate, Potassium Phosphate; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dry Eye, Neurotrophic Keratitis
Interventions: Cenegermin Ophthalmic Solution [Oxervate]; Drug
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Does Overpractice Improve Motor Learning?

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder

Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Intensive Rehabilitation

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study

A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment

GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain

Sleep and Circadian Interventions for College Students at High Risk of Suicide

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Trans Auricular Vagus Nerve Stimulation (taVNS) and Robotic Training for Paralyzed Arm After Stroke

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Assessment of Energy Balance

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth

Feasibility of Home-based tES for Older Adults at Risk of Falling

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Phosphate in Acute Pancreatitis

DOMPE -MT Neurotrophic Keratitis